STN: Text & Investor's name Sourch

FILE 'HOME' ENTERED AT 15:43:23 ON 02 APR 2002

=> file medline

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

0.21 SESSION

FILE 'MEDLINE' ENTERED AT 15:43:56 ON 02 APR 2002

FILE LAST UPDATED: 1 APR 2002 (20020401/UP). FILE COVERS 1958 TO DATE.

On April 22, 2001, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE now contains IN-PROCESS records. See HELP CONTENT for details.

MEDLINE is now updated 4 times per week. A new current-awareness alert frequency (EVERYUPDATE) is available. See HELP UPDATE for more information.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2001 vocabulary. Enter HELP THESAURUS for details.

The OLDMEDLINE file segment now contains data from 1958 through 1965. Enter HELP CONTENT for details.

Left, right, and simultaneous left and right truncation are available in the Basic Index. See HELP SFIELDS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

=> s recombinant interferon and polymer and antioxidant?

188299 RECOMBINANT

4875 RECOMBINANTS

190862 RECOMBINANT

(RECOMBINANT OR RECOMBINANTS)

67884 INTERFERON

17095 INTERFERONS

72278 INTERFERON

(INTERFERON OR INTERFERONS)

2384 RECOMBINANT INTERFERON

(RECOMBINANT (W) INTERFERON)

17785 POLYMER

30166 POLYMERS

40938 POLYMER

(POLYMER OR POLYMERS)

33802 ANTIOXIDANT?

L1 0 RECOMBINANT INTERFERON AND POLYMER AND ANTIOXIDANT?

=> s recombinant interferon and polymer and antioxidant

188299 RECOMBINANT

4875 RECOMBINANTS

190862 RECOMBINANT

(RECOMBINANT OR RECOMBINANTS)

67884 INTERFERON

17095 INTERFERONS

72278 INTERFERON

(INTERFERON OR INTERFERONS)

2384 RECOMBINANT INTERFERON

(RECOMBINANT (W) INTERFERON)

17785 POLYMER

30166 POLYMERS

40938 POLYMER

(POLYMER OR POLYMERS)

20999 ANTIOXIDANT

24083 ANTIOXIDANTS

33797 ANTIOXIDANT

(ANTIOXIDANT OR ANTIOXIDANTS)

```
Г
```

```
=> s recombinant interferon and polymer
        188299 RECOMBINANT
          4875 RECOMBINANTS
        190862 RECOMBINANT
                  (RECOMBINANT OR RECOMBINANTS)
         67884 INTERFERON
         17095 INTERFERONS
         72278 INTERFERON
                 (INTERFERON OR INTERFERONS)
          2384 RECOMBINANT INTERFERON
                 (RECOMBINANT (W) INTERFERON)
         17785 POLYMER
         30166 POLYMERS
         40938 POLYMER
                  (POLYMER OR POLYMERS)
             4 RECOMBINANT INTERFERON AND POLYMER
L3
=> d L3 1-3
L3
     ANSWER 1 OF 4
                       MEDLINE
ΑN
     97320978
                  MEDLINE
                PubMed ID: 9177709
DN
     97320978
     Positional isomers of monopegylated interferon alpha-2a: isolation,
ΤI
     characterization, and biological activity.
     Monkarsh S P; Ma Y; Aglione A; Bailon P; Ciolek D; DeBarbieri B; Graves M
     C; Hollfelder K; Michel H; Palleroni A; Porter J E; Russoman E; Roy S; Pan
     Y C
CS
     Department of Biopharmaceuticals, Hoffmann-La Roche Inc., Nutley, New
     Jersey 07110, USA.
     ANALYTICAL BIOCHEMISTRY, (1997 May 1) 247 (2) 434-40.
SO
     Journal code: 4NK; 0370535. ISSN: 0003-2697.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Priority Journals
     199707
EM
     Entered STN: 19970721
ED
     Last Updated on STN: 19970721
     Entered Medline: 19970710
L3
     ANSWER 2 OF 4
                       MEDLINE
ΑN
     97005215
                  MEDLINE
     97005215
                PubMed ID: 8852526
DN
TΙ
     Newer versus older treatments for relapsing-remitting multiple sclerosis.
     Weinstock-Guttman B; Cohen J A
ΑU
     Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland
CS
     Clinic Foundation, Ohio, USA.
SO
     DRUG SAFETY, (1996 Feb) 14 (2) 121-30. Ref: 22
     Journal code: AHQ; 9002928. ISSN: 0114-5916.
CY
     New Zealand
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
     (REVIEW, TUTORIAL)
LΑ
     English
FS
     Priority Journals
EM
     199612
     Entered STN: 19970128
ED
     Last Updated on STN: 19970128
     Entered Medline: 19961212
L3
     ANSWER 3 OF 4
                       MEDLINE
AN
     89168263
                 MEDLINE
DN
     89168263
                PubMed ID: 2493987
ΤI
     Tumor cytotoxicity of human monocyte membrane-bound interleukin-1 alpha
     induced by synergistic actions of interferon-gamma and synthetic
     acyltripeptide, FK-565.
```

```
Inamura N; Sone S; Okubo A; ishige E; Nakanishi M; Ogura T
Third Department of Internal Medicine, University of Tokushima School of
ΑU
CS
     Medicine, Japan.
     CANCER IMMUNOLOGY, IMMUNOTHERAPY, (1989) 28 (3) 164-70. Journal code: CN3; 8605732. ISSN: 0340-7004.
SO
     GERMANY, WEST: Germany, Federal Republic of
CY
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
FS
     Priority Journals
EM
     198905
ED
     Entered STN: 19900306
     Last Updated on STN: 19900306
     Entered Medline: 19890508
=> s recombinant interferon and PVP
         188299 RECOMBINANT
           4875 RECOMBINANTS
         190862 RECOMBINANT
                   (RECOMBINANT OR RECOMBINANTS)
          67884 INTERFERON
          17095 INTERFERONS
          72278 INTERFERON
                   (INTERFERON OR INTERFERONS)
           2384 RECOMBINANT INTERFERON
                   (RECOMBINANT (W) INTERFERON)
           1321 PVP
             10 PVPS
           1327 PVP
                   (PVP OR PVPS)
L4
              O RECOMBINANT INTERFERON AND PVP
=> s recombinant interferon and PVP
         188299 RECOMBINANT
           4875 RECOMBINANTS
         190862 RECOMBINANT
                   (RECOMBINANT OR RECOMBINANTS)
          67884 INTERFERON
          17095 INTERFERONS
          72278 INTERFERON
                   (INTERFERON OR INTERFERONS)
           2384 RECOMBINANT INTERFERON
                   (RECOMBINANT (W) INTERFERON)
           1321 PVP
             10 PVPS
           1327 PVP
                   (PVP OR PVPS)
              O RECOMBINANT INTERFERON AND PVP
L5
=> s interferon and PVP
          67884 INTERFERON
          17095 INTERFERONS
          72278 INTERFERON
                   (INTERFERON OR INTERFERONS)
           1321 PVP
             10 PVPS
           1327 PVP
                   (PVP OR PVPS)
L6
              6 INTERFERON AND PVP
=> d L6 1-6
     ANSWER 1 OF 6
L6
                         MEDLINE
AN
     2001009587
                      MEDLINE
DN
     20444493 PubMed ID: 10986558
ΤI
     Combination of interleukin 12 and interferon alpha gene therapy
     induces a synergistic antitumor response against colon and renal cell
     carcinoma.
```

```
ΑU
     Mendiratta S K; Quezada A; Marr M; Thull N M; Bishop J S; No: trom J L;
CS
     Valentis, Inc., The Woodlands, TX 77381, USA.
     HUMAN GENE THERAPY, (2000 Sep 1) 11 (13) 1851-62. 
Journal code: A12. ISSN: 1043-0342.
SO
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Priority Journals
EM
     200010
ED
     Entered STN: 20010322
     Last Updated on STN: 20010322
     Entered Medline: 20001026
     ANSWER 2 OF 6
L6
                        MEDLINE
ΑN
     2000227756
                     MEDLINE
     20227756
                 PubMed ID: 10762565
DN
TΙ
     Biomaterial-associated persistence of Staphylococcus epidermidis in
     pericatheter macrophages.
     Boelens J J; Dankert J; Murk J L; Weening J J; van der Poll T; Dingemans K
ΑU
     P; Koole L; Laman J D; Zaat S A
CS
     Dept. of Pediatrics, Leiden University Medical Center, 2300 RC Leiden, The
     Netherlands.. Boelensjj@yahoo.com
SO
     JOURNAL OF INFECTIOUS DISEASES, (2000 Apr) 181 (4) 1337-49.
     Journal code: IH3; 0413675. ISSN: 0022-1899.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Abridged Index Medicus Journals; Priority Journals
EM
     200006
ED
     Entered STN: 20000613
     Last Updated on STN: 20000613
     Entered Medline: 20000601
     ANSWER 3 OF 6
L6
                        MEDLINE
     1999434733
ΑN
                     MEDLINE
DN
     99434733 PubMed ID: 10505108
TΙ
     Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system
     to murine renal and colon carcinoma results in potent antitumor immunity.
ΑU
     Mendiratta S K; Quezada A; Matar M; Wang J; Hebel H L; Long S; Nordstrom J
     L; Pericle F
CS
     GeneMedicine, Inc. The Woodlands, TX 77381-4248, USA.
SO
     GENE THERAPY, (1999 May) 6 (5) 833-9.
     Journal code: CCE; 9421525. ISSN: 0969-7128.
CY
     ENGLAND: United Kingdom
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Priority Journals
EM
     199910
ED
     Entered STN: 20000111
     Last Updated on STN: 20000111
     Entered Medline: 19991022
     ANSWER 4 OF 6
1.6
                        MEDLINE
ΑN
     1999008308
                     MEDLINE
               PubMed ID: 9794206
DN
     99008308
     Nonviral interferon alpha gene therapy inhibits growth of
TΙ
     established tumors by eliciting a systemic immune response.
     Coleman M; Muller S; Quezada A; Mendiratta S K; Wang J; Thull N M; Bishop
ΑU
     J; Matar M; Mester J; Pericle F
     GeneMedicine, Inc., The Woodlands, TX 77381-4248, USA. HUMAN GENE THERAPY, (1998 Oct 10) 9 (15) 2223-30.
CS
SO
     Journal code: A12; 9008950. ISSN: 1043-0342.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Priority Journals
EM
     199901
```

```
ED
     Entered STN: 19990115
     Last Updated on STN: 1999011
     Entered Medline: 19990105
     ANSWER 5 OF 6
L6
                       MEDLINE
                  MEDLINE
ΑN
     93170852
                PubMed ID: 7679660
DN
     93170852
     B-cell activation following murine cytomegalovirus infection: implications
TΙ
     for autoimmunity.
     Price P; Olver S D; Gibbons A E; Shellam G R
ΑU
     Department of Microbiology, University of Western Australia, Nedlands.
CS
     IMMUNOLOGY, (1993 Jan) 78 (1) 14-21.
SO
     Journal code: GH7; 0374672. ISSN: 0019-2805.
CY
     ENGLAND: United Kingdom
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Priority Journals
EM
     199303
ED
     Entered STN: 19930402
     Last Updated on STN: 19960129
     Entered Medline: 19930324
     ANSWER 6 OF 6
L6
                       MEDLINE
AN
     91108079
                  MEDLINE
DN
     91108079
                PubMed ID: 2125618
TΙ
     A method for preparing biologically active aqueous cyclosporin A solutions
     avoiding the use of detergents or organic solvents.
ΑU
     Yonish-Rouach E; Shinitzky M; Rubinstein M
     Department of Molecular Genetics and Virology, Weizmann Institute of
CS
     Science, Rehovot, Israel.
     JOURNAL OF IMMUNOLOGICAL METHODS, (1990 Dec 31) 135 (1-2) 147-53.
SO
     Journal code: IFE; 1305440. ISSN: 0022-1759.
CY
     Netherlands
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
FS
     Priority Journals
EM
     199102
ΕD
     Entered STN: 19910329
     Last Updated on STN: 19980206
     Entered Medline: 19910227
=> s interferon and nasal drop?
         67884 INTERFERON
         17095 INTERFERONS
         72278 INTERFERON
                 (INTERFERON OR INTERFERONS)
         47137 NASAL
            49 NASALS
         47165 NASAL
                 (NASAL OR NASALS)
         55518 DROP?
           125 NASAL DROP?
                 (NASAL(W) DROP?)
L7
             5 INTERFERON AND NASAL DROP?
=> d L7 1-5
1.7
     ANSWER 1 OF 5
                       MEDLINE
ΑN
     92368579
                  MEDLINE
DN
     92368579
                PubMed ID: 1323974
TΙ
     Otologic effects of interferon beta serine in experimental
     rhinovirus colds.
ΑU
     Sperber S J; Doyle W J; McBride T P; Sorrentino J V; Riker D K; Hayden F G
     Department of Internal Medicine, University of Virginia School of
CS
     Medicine, Charlottesville.
NC
     T32AI-07046 (NIAID)
     ARCHIVES OF OTOLARYNGOLOGY -- HEAD AND NECK SURGERY, (1992 Sep) 118 (9)
SO
```

```
933-6.
     Journal code: ALQ; 8603209. ISSN: 0886-4470.
CY
     United States
DT
     (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
LA
     English
     Abridged Index Medicus Journals; Priority Journals
FS
EM
     199209
ED
     Entered STN: 19921009
     Last Updated on STN: 19960129
     Entered Medline: 19920922
L7
     ANSWER 2 OF 5
                       MEDLINE
ΑN
     90010266
                  MEDLINE
                PubMed ID: 2551976
DN
     90010266
     Ineffectiveness of recombinant interferon-beta serine
TΙ
     nasal drops for prophylaxis of natural colds.
     Sperber S J; Levine P A; Sorrentino J V; Riker D K; Hayden F G
ΑU
     Department of Internal Medicine, University of Virginia School of
CS
     Medicine, Charlottesville.
     T32AI-07046 (NIAID)
NC
     JOURNAL OF INFECTIOUS DISEASES, (1989 Oct) 160 (4) 700-5.
SO
     Journal code: IH3; 0413675. ISSN: 0022-1899.
CY
     United States
DT
     (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
     English
LA
FS
     Abridged Index Medicus Journals; Priority Journals
     198910
EM
ED
     Entered STN: 19900328
     Last Updated on STN: 19970203
     Entered Medline: 19891028
     ANSWER 3 OF 5
                       MEDLINE
L7
     88274084
                  MEDLINE
AN
                PubMed ID: 2839579
DN
     88274084
TI
     Tolerance and efficacy of intranasal administration of recombinant beta
     serine interferon in healthy adults.
     Sperber S J; Levine P A; Innes D J; Mills S E; Hayden F G
ΑU
     Department of Internal Medicine, University of Virginia School of
CS
     Medicine, Charlottesville.
NC
     T32AI-07046 (NIAID)
SO
     JOURNAL OF INFECTIOUS DISEASES, (1988 Jul) 158 (1) 166-75.
     Journal code: IH3; 0413675. ISSN: 0022-1899.
CY
     United States
DT
     (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
LA
     English
FS
     Abridged Index Medicus Journals; Priority Journals
EM
     198808
ED
     Entered STN: 19900308
     Last Updated on STN: 19970203
     Entered Medline: 19880817
     ANSWER 4 OF 5
L7
                       MEDLINE
ΑN
     84290843
                  MEDLINE
DN
     84290843
                PubMed ID: 6381610
TI
     Intranasal interferon-alpha 2 treatment of experimental
     rhinoviral colds.
ΑU
     Hayden F G; Gwaltney J M Jr
NC
     R23-AI-17034 (NIAID)
SO
     JOURNAL OF INFECTIOUS DISEASES, (1984 Aug) 150 (2) 174-80.
     Journal code: IH3; 0413675. ISSN: 0022-1899.
CY
     United States
DT
     (CLINICAL TRIAL)
```

```
Journal; Article; (JOURNAL AN
     (RANDOMIZED CONTROLLED TRIAL)
LA
     English
FS
     Abridged Index Medicus Journals; Priority Journals
EΜ
     198410
     Entered STN: 19900320
ED
     Last Updated on STN: 19970203
     Entered Medline: 19841015
L7
     ANSWER 5 OF 5
                       MEDLINE
     75196707
                  MEDLINE
ΑN
     75196707
                PubMed ID: 1170566
DN
ΤI
     Induction of interferon in man by vaccines.
ΑU
SO
     PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, (1975
     May) 149 (1) 266-70.
     Journal code: PXZ; 7505892. ISSN: 0037-9727.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Priority Journals
ĖΜ
     197509
     Entered STN: 19900310
ED
     Last Updated on STN: 19900310
     Entered Medline: 19750929
=> s recombinant interferon and antioxidant?
        188299 RECOMBINANT
          4875 RECOMBINANTS
        190862 RECOMBINANT
                  (RECOMBINANT OR RECOMBINANTS)
         67884 INTERFERON
         17095 INTERFERONS
         72278 INTERFERON
                  (INTERFERON OR INTERFERONS)
          2384 RECOMBINANT INTERFERON
                  (RECOMBINANT (W) INTERFERON)
         33802 ANTIOXIDANT?
             4 RECOMBINANT INTERFERON AND ANTIOXIDANT?
1.8
=> d L8 1-4
L8
     ANSWER 1 OF 4
                       MEDLINE
AN
     1999295021
                    MEDLINE
DN
              PubMed ID: 10366945
ΤI
     [Strategy and tactics of radiation protection of the personnel in light of
     future work on stabilization and reorganization of the "Shelter" compound
     into radiologically safe system].
     Strategiia i taktika radiologicheskoi zashchity personala v sviazi s
     predstoiashchimi rabotami po stabilizatsii i reorganizatsii ob''ekta
     "Ukrytie" v radiatsionno bezopasnuiu sistemu.
     Seniuk O F; Danilov V M
ΑU
     ISTC Shelter NAcSci of Ukraine, Chernobyl.
CS
SO
     RADIATSIONNAIA BIOLOGIIA, RADIOECOLOGIIA, (1999 Mar-Jun) 39 (2-3) 227-37.
     Journal code: BWZ; 9317212. ISSN: 0869-8031.
CY
     RUSSIA: Russian Federation
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     Russian
FS
     Priority Journals
ΕM
     199907
ED
     Entered STN: 19990714
     Last Updated on STN: 19990714
     Entered Medline: 19990701
L8
     ANSWER 2 OF 4
                       MEDLINE
     94350232
                  MEDLINE
ΑN
DN
     94350232
                PubMed ID: 8070686
```

```
T.I
     Influenza virus induces expression of antioxidant genes in hu
     epithelial cells.
     Jacoby D B; Choi A M
     Division of Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and
CS
     Allergy Center, Baltimore, MD 21224.
     AG00516 (NIA)
NC
     HL47126 (NHLBI)
     FREE RADICAL BIOLOGY AND MEDICINE, (1994 Jun) 16 (6) 821-4.
SO
     Journal code: FRE; 8709159. ISSN: 0891-5849.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
FS
     Priority Journals
EM
     199409
F.D
     Entered STN: 19941006
     Last Updated on STN: 19941006
     Entered Medline: 19940926
     ANSWER 3 OF 4
r_8
                       MEDLINE
ΑN
     92310903
                  MEDLINE
                PubMed ID: 1614804
DN
     92310903
TΙ
     [Effectiveness of using recombinant interferon alfa2
     (reaferon) combined with antioxidants in children with acute
     hepatitis B].
     Effektivnost' primeneniia rekombinantnogo alfa2 interferona (reaferona) v
     komplekse s antioksidantami pri ostrom virusnom gepatite B u detei.
ΑU
     Reizis A R; Malinovskaia V V; Shekhade S; Drondina A K; Nikitina T S;
     Markarian A S; Nazarenko I V; Mikhailov M I
SO
     PEDIATRIIA, (1992) (1) 60-4.
     Journal code: OYL; 0405563. ISSN: 0031-403X.
CY
     USSR
DT
     (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
     Russian
LA
FS
     Priority Journals
     199207
ΕM
ED
     Entered STN: 19920807
     Last Updated on STN: 20000303
     Entered Medline: 19920727
L8
     ANSWER 4 OF 4
                       MEDLINE
ΑN
     86306105
                  MEDLINE
DN
     86306105
                PubMed ID: 3018103
TI
     Induction of xanthine oxidase and heme oxygenase and depression of liver
     drug metabolism by interferon: a study with different recombinant
     interferons.
ΑU
     Ghezzi P; Saccardo B; Bianchi M
     JOURNAL OF INTERFERON RESEARCH, (1986 Jun) 6 (3) 251-6.
SO
     Journal code: IJI; 8100396. ISSN: 0197-8357.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
     English
LA
     Priority Journals
FS
EM
     198610
ΕD
     Entered STN: 19900321
     Last Updated on STN: 19980206
     Entered Medline: 19861023
=> s (Gaponjuk, P? or Gaponjuk P?)/au
             O GAPONJUK, P?/AU
             O GAPONJUK P?/AU
             O (GAPONJUK, P? OR GAPONJUK P?)/AU
L9
```

East: interferon and (PP or poly othylene adj 1 oxid) and antioxidant?

· ·	_	1	1			<del></del>		1
	บ	1	Do	cument ID	Issue Date	Pages	Title	Current OR
1			US A	4606917	19860819	7	Synergistic antiviral composition	424/85.6
2	Ø		US A	4857316	19890815	7	Synergistic antiviral composition	424/85.6
3	×		US A	5232712	19930803	9	Extrusion apparatus and systems	425/133.1
4			US A	5334612	19940802	14	Pharmaceutical compositions containing as active substance sulphur-containing carboxylic acids and their use in combating retroviruses	514/440
5			US A	5380754	19950110	13	Topical composition enhancing healing of viral lesions	514/513
6			US A	5418154	19950523	21	Method of preparing elongated seamless capsules containing biological material	435/182
7	×		US A	5472706	19951205	10	Dry compositions for preparing submicron emulsions	424/450
8	⊠		US A	5542935	19960806	66	Therapeutic delivery systems related applications	604/190
9	×		US A	5554148	19960910	20	Renewable neural implant device and method	604/890.1
10	×		US A	5559156	19960924	8	Method for treating animals infected with Babesia spp.	514/682
11	☒		US A	5561164	19961001	8	Method of treatng protozoal infections caused by microsporidia	514/682
12	⊠	1 1 3	US A	5567738	19961022	6	Use of 2-(4-(4-chlorophenyl)cy clohexyl)-3-hydroxy-1,4 -Naphthoquinone for the treatment of cancer	514/682
13	Ø		US A	5569670	19961029	11	Combination medications containing alpha-lipoic acid and related	514/440

				_		1		ı		
	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
1	435/70.5; 435/804		Eppstein, Deborah A.	⊠						
2	424/85.4		Eppstein, Deborah A.							
3	425/70		Mills, John F. et al.							
4	424/439; 514/557; 514/558; 514/559; 514/707		Kalden, Joachim et al.							
5	514/934		Miller, Bruce W. et al.	⊠						
6	264/4; 264/4.7; 424/451; 425/382R; 425/382.2; 435/178; 435/179; 530/817		Aebischer, Patrick et al.	×						
7	264/4.1; 264/4.3; 514/937; 514/938; 514/939; 514/943		Friedman, Doron et al.							
8	424/450; 600/458		Unger, Evan C. et al.							
9	604/265; 604/43; 604/93.01		Aebischer, Patrick et al.							
10			Gutteridge, Winston E. et al.							
11			Gutteridge, Winston E. et al.							
12			Hudson, Alan T.							
13	514/866		Weischer, Carl-Heinrich et al.							

	I	mage Doc. Displayed	PT
1	us	4606917	
2	us	4857316	
3	us	5232712	
4	US	5334612	
5	US	5380754	
6	US	5418154	
7	US	5472706	
8	US	5542935	
9	US	5554148	
10	US	5559156	
11	US	5561164	
12	US	5567738	
13	US	5569670	

	σ	1	De	cument ID	Issue Date	Pages	Title	Current OR
14			US A	5578567	19961126	11	Nasal pharmaceutical composition	514/12
15	Ø		US A	5580575	19961203	55	Therapeutic drug delivery systems	424/450
16	⊠		US A	5603955	19970218	20	Enhanced loading of solutes into polymer gels	424/484
17	⊠		US A	5613958	19970325	25	Transdermal delivery systems for the modulated administration of drugs	604/307
18	⊠	:	US A	5618528	19970408	18	Biologically compatible linear block copolymers of polyalkylene oxide and peptide units	424/78.3
19	$\boxtimes$		US A	5643773	19970701	19	Preparation of elongated seamless capsules containing a coaxial rod and biological material	435/182
20	×		US A	5652274	19970729	172	Therapeutic-wound healing compositions and methods for preparing and using same	514/724
21			US A	5656289	19970812	23	Pharmaceutical formulations that have a biologically active hydrophilic phase and a chylomicra-containing hydrophobic phase	424/455

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
14	530/324		Cardinaux, Fran.cedilla.ois et al.	⊠						
15			Unger, Evan C. et al.							
16	424/486; 424/487; 424/488; 514/944; 516/102; 516/104; 516/105; 516/106; 516/107		Gehrke, Stevin H. et al.							
17	424/449; 514/947; 602/52; 602/54; 602/58; 604/890.1		Kochinke, Frank et al.							
18	424/78.38; 525/423; 525/430; 525/54.1		Cooper, Eugene R. et al.							
19	264/4; 264/4.7; 424/451; 425/382R; 425/382.2; 435/178; 435/179; 435/325; 435/368; 435/382; 530/817		Aebischer, Patrick et al.							
20	514/461; 514/562; 514/567; 514/725; 514/774; 514/784		Martin, Alain							
21	424/450; 424/451; 424/456; 424/463; 514/2; 514/21; 514/3; 514/937; 514/938; 514/941; 514/943		Cho, Young W. et al.	×						

	I	mage Doc. Displayed	PT
14	บร	5578567	
15	US	5580575	
.16	US	5603955	
17	US	5613958	
18	US	5618528	
19	US	5643773	
20	US	5652274	
21	US	5656289	

	ซ	1	Do	cument ID	Issue Date	Pages	Title	Current OR
22	⊠		US A	5672359	19970930	13	Multicompartment hard capsule with control release properties	424/463
23			US A	5696160	19971209	13	Topical composition enhancing healing of viral lesions	514/513
24	⊠		US A	5716981	19980210	121	Anti-angiogenic compositions and methods of use	514/449
25	⊠		US A	5728735	19980317	7	Pharmaceutical composition containing Ralphalipoic acid or Salphalipoic acid as active ingredient	514/560
26	⊠	;     :	US A	5750142	19980512	11	Dry compositions for preparing submicron emulsions	424/450
27	×		US A	5770222	19980623	54	Therapeutic drug delivery systems	424/450
28	⊠		US A	5773286	19980630	19	Inner supported biocompatible cell capsules	435/297.1
29	×		US A	5780514	19980714	8	Antiprotozoal medicaments	514/682

	<u> </u>	Datai see 1	T		~	T	1	I		Γ
	Current XRef	Retrieval Classif	Inventor	S	С	P	2	3	4	5
22	424/408; 424/452; 424/453; 424/454; 424/455; 424/456		Digenis, George A. et al.							
23	514/934		Miller, Bruce W. et al.	×						
24	128/898; 526/304; 528/421; 604/20; 604/21; 604/269; 604/508; 606/198; 623/1.15		Hunter, William L. et al.							
25			Ulrich, Heinz et al.				Ġ			
26	264/4.1; 264/4.3; 514/937; 514/938; 514/939; 514/943	-	Friedman, Doron et al.							
27	264/4.1; 264/4.3; 264/4.6; 424/1.21; 424/489; 424/9.321; 424/9.51; 436/829		Unger, Evan C. et al.							
28	424/93.7; 435/174; 435/182; 435/289.1; 435/382; 435/395; 604/890.1		Dionne, Keith E. et al.							
29			Gutteridge, Winston Edward et al.							

	I	mage Doc. Displayed	PT
22	US	5672359	
23	US	5696160	
24	US	5716981	
25	US	5728735	
26	US	5750142	
27	US	5770222	
28	US	5773286	
29	US	5780514	

	U	1	Document ID	Issue Date	Pages	Title	Current OR
30			US 5786216 A	19980728	23	Inner-supported, biocompatible cell capsules	435/402
31	⊠		US 5840338 A	19981124	53	Loading of biologically active solutes into polymer gels	424/488
32	×		US 5849800 A	19981215	9	Use of amantadine for treatment of Hepatitis	514/647
33	×		US 5853713 A	19981229	18	Biologically compatible linear block copolymers of polyalkylene oxide and peptide units	424/78.38
34	⊠		US 5856362 A	19990105	6	Medicaments for the treatment of toxoplasmosis	514/682
35	⊠		US 5886026 A	19990323	120	Anti-angiogenic compositions and methods of use	514/449
36	⊠		US 5900238 A	19990504	14	Vaccine delivery system	424/184.1
37	⊠		US 5962477 A	19991005	51	Screening methods for cytokine inhibitors	514/327
38	⊠		US 5972369 A	19991026	12	Diffusional implantable delivery system	424/424
39	⊠		US 5994341 A	19991130	119	Anti-angiogenic Compositions and methods for the treatment of arthritis	514/449
40	⊠		US 5994372 A	19991130	64	Peripherally active anti-hyperalgesic opiates	514/327

	Current	Retrieval				1	Ι		Г	
	XRef	Classif	Inventor	S	С	P	2	3	4	5
30	424/422; 424/93.7; 435/182; 435/395; 435/400; 435/401; 604/890.1		Dionne, Keith E. et al.							
31	424/484; 424/486; 424/487; 514/944; 516/99		Roos, Eric J. et al.							
32			Smith, Jill P.							
33	514/773; 525/523; 525/54.11; 530/345		Cooper, Eugene R. et al.							
34	568/328		Hudson, Alan Thomas							
35			Hunter, William L. et al.							
36	424/185.1; 424/192.1; 424/198.1; 424/278.1; 424/489; 424/490; 424/496; 424/497; 424/85.2		Gombotz, Wayne R. et al.							
37	424/78.05		Mak, Vivian							
38	424/425; 604/892.1		Roorda, Wouter E. et al.							
39	514/250; 514/825; 514/886		Hunter, William L. et al.							
40			Yaksh, Tony L.							

	I	mage Doc. Displayed	PT
30	US	5786216	
31	US	5840338	
32	US	5849800	
33	US	5853713	
34	US	5856362	
35	US	5886026	
36	US	5900238	
37	US	5962477	
38	US	5972369	
39	US	5994341	
40	US	5994372	

	υ	1	Do	cument ID	Issue Date	Pages	Title	Current OR
41	⊠	: F 1	US A	6001606	19991214	117	Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby	435/69.5
42	×		US A	6004582	19991221	14	Multi-layered osmotic device	424/473
43	⊠		US A	6025158	20000215	240	Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies	435/69.1
44	×		US A	6028169	20000222	105	Chemokine .beta6 antagonists	530/324
45	⊠		US A	6046177	20000404	59	Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations	514/58
46	×	: I I	US A	6117980	20000912	138	Humanized anti-IL-8 monoclonal antibodies	530/387.3
47	$\boxtimes$		US A	6133426	20001017	: ') /  ()	Humanized anti-IL-8 monoclonal antibodies	530/388.23

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
41	424/85.1; 435/252.3; 435/254.11; 435/320.1; 435/325; 435/471; 435/71.2; 536/23.1; 536/23.5; 930/140		Ruben, Steven M. et al.							
42	424/468; 424/472; 424/474; 424/475; 424/476; 424/479; 424/482		Faour, Joaquina et al.							
43			Gonzalez, Tania N. et al.							
44	530/300; 530/397; 530/399		Kreider, Brent L. et al.							
45	514/778; 514/964; 514/965; 536/103		Stella, Valentino J. et al.							
46	424/133.1; 424/135.1; 424/145.1; 530/387.1; 530/388.23		Gonzalez, Tania N. et al.							
47	424/130.1; 424/139.1; 424/141.1; 424/142.1; 424/145.1; 530/387.1; 530/388.1; 530/388.1; 530/389.1; 530/389.2		Gonzalez, Tania N. et al.							

	I	mage Doc. Displayed	PT
41	US	. 6001606	
42	US	6004582	
43	US	6025158	
44	US	6028169	
45	us	6046177	
46	US	6117980	
47	US	6133426	

	บ	1	Do	cument ID	Issue Date	Pages	Title	Current OR
48	⊠		US A	6139832	20001031	53	Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides	424/85.1
49	×		US A	6156312	20001205	21	Agents, affecting the hyperactivated immunological effector cells	424/144.1
50	⊠		US B1	6169920	20010102	14	Iontophoretic drug delivery apparatus	604/20
51	$\boxtimes$		US B1	6174873	20010116	12	Oral administration of adenosine analogs	514/45
52	⊠		US B1	6183752	20010206	į.	Restenosis/atherosclero sis diagnosis, prophylaxis and therapy	424/199.1
53	⊠		US B1	6190691	20010220		Methods for treating inflammatory conditions	424/449
54	⊠		US B1	6194391	20010227		3'-azido-2',3'-dideoxyu ridine administration to treat HIV and related test protocol	514/50

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
48	435/252.3; 435/320.1; 435/325; 435/471; 435/69.5; 435/71.1; 435/71.2; 530/351; 536/23.5; 930/140		Li, Haodong et al.							
49			Leskovar, Peter							
50	607/152		Haak, Ronald P. et al.							
51	424/457; 424/458; 424/460; 424/463; 424/464; 424/469; 424/470; 514/46; 514/885; 514/908; 514/959; 514/964		Wrenn, Jr., Simeon M.							
52	424/230.1; 424/277.1; 424/93.2; 435/320.1; 514/44		Epstein, Stephen E. et al.							
53	514/859; 514/861; 514/863; 514/886; 514/887; 604/20		Mak, Vivien H. W.							
54	435/6; 514/253.01; 514/263.23; 514/45; 514/46; 514/47; 514/48; 514/49; 514/51		Schinazi, Raymond F. et al.							

	I	mage Doc. Displayed	PT
48	US	6139832	
49	US	6156312	
50	US	6169920	
51	US	6174873	
52	US	6183752	
53			
54			

	ט	1	Document_ID	Issue Date	Pages	Title	Current OR
55			US 6207665 B1	20010327		Piperazine derivatives and their use as anti-inflammatory agents	514/235.8
56			US 6248363 B1	20010619		Solid carriers for improved delivery of active ingredients in pharmaceutical compositions	424/497

	1		·			· · · ·		_	Γ	$\overline{}$
	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
55	514/252.11; 514/254.01; 514/254.02; 514/254.05; 514/254.08; 514/254.1; 514/255.01; 544/121; 544/231; 544/357; 544/366; 544/366; 544/370; 544/373; 544/373; 544/379; 544/391		Bauman, John G. et al.							
5,6	424/422; 424/427; 424/430; 424/433; 424/435; 424/436; 424/4451; 424/457; 424/463; 424/463; 424/466; 424/470; 424/470; 424/476; 424/476; 424/476; 424/482; 424/489; 424/498; 514/772:3; 514/773; 514/779; 514/785; 514/785;		Patel, Mahesh V. et al.							

		Image Doc. Displayed	PT
	55		
C)	56		

	ט	1	Do	cument_ID	Issue Date	Pages	Title	Current OR
57	⊠		US B1	6271254	20010807		Pharmaceutical compositions containing Ralphalipoic acid or Salphalipoic acid as active ingredient	514/440
58			US B1	6280728	20010828		Treatment of hepatitis C virus infection using a protease and a flavonoid	424/94.64
59	⊠		US B1	6294170	20010925		Composition and method for treating inflammatory diseases	424/134.1
60			US B1	6294655	20010925		Anti-interleukin-1 receptor antagonist antibodies and uses thereof	530/388.23
61	$\boxtimes$		US B1	6309663	20011030		Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents	424/450
62	Ø		US B1	6317629	20011113		Iontophoretic drug delivery apparatus	604/20

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
57	548/144		Ulrich, Heinz et al.							
58	424/94.65; 514/21; 514/25; 514/27		Stauder, Gerhard et al.							
59	514/12; 530/324		Boone, Thomas C. et al.							
60	424/134.1; 424/139.1; 424/141.1; 424/145.1; 435/7.1; 436/501; 530/350; 530/387.9; 530/388.1; 530/388.15; 530/389.1; 530/391.1; 530/391.3; 536/23.5		Ford, John et al.							
61	424/435; 424/451; 424/455; 424/456; 424/463; 424/464; 424/489; 424/499; 424/502; 514/937; 514/938; 514/940; 514/941; 514/941; 514/943; 514/975		Patel, Mahesh V. et al.							
62	439/86; 607/152; 607/153		Haak, Ronald P. et al.							

	Image Doc. Displayed	PT
57		
58		
59		
60		
61		
62		

	ט	1	Do	cument ID	Issue Pages Title		Title	Current OR	
63	×		US B1	6322770	20011127		Indazole vitronectin receptor antagonist pharmaceuticals	424/1.65	
64	⊠		US B1	6335013	20020101	98	Methods and materials relating to CD39-like polypeptides	424/94.61	
65			US B1	6337072	20020108	60	Interleukin-1 receptor antagonist and recombinant production thereof	424/198.1	
66	⊠		US B1	6339141	20020115	41	Interleukin-1 Hy2 materials and methods	530/351	
67	⊠		US B1	6350431	20020226	63	Compounds	424/9.6	
68	⊠		US B1	6352721	20020305	18	Combined diffusion/osmotic pumping drug delivery system	424/473	
69			US B1	6365726	20020402	62	Polynucleotides encoding IL-1 Hy2 polypeptides	536/23.52	

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
63	424/1.11; 424/9.1; 424/9.3; 424/9.34; 530/300; 534/14; 548/361.1		Rajopadhye, Milind et al.							
64	514/12		Ford, John et al.							
65	424/1.69; 435/252.3; 435/320.1; 435/325; 435/69.1; 435/69.52; 514/2; 530/350; 530/351; 530/402; 536/23.5		Ford, John et al.							
66	424/143.1; 424/145.1; 424/85.2		Ballinger, Dennis G. et al.							
67	548/223; 549/402; 549/427; 549/455		Snow, Robert Allen et al.							
68	424/422; 424/423; 424/424; 424/435; 424/436; 424/437; 424/437; 424/468; 424/472; 514/772.3; 514/781; 514/784; 514/785; 514/786	,	Faour, Joaquina							
69	435/320.1; 435/69.1; 435/69.52; 536/23.1; 536/23.5; 536/24.31		Ballinger, Dennis G. et al.	⊠						

	Image Doc. Displayed						
63	,						
64	US	6335013					
65	US	6337072					
66	US	6.339141					
67	US	6350431					
68	US	6352721					
69	US	6365726					

	บ	1	Document_ID	Issue Date	Pages	Title	Current	OR
70			US 6365768 B1	20020402	57	Interleukin-1 and tumor necrosis factorsalpha. modulators, syntheses of said modulators and methods of using modulators	560/117	

	Current XRef	Retrieval Classif	Inventor	S	С	P	2	3	4	5
70	560/116; 562/498; 562/499		Palladino, Michael et al.	⊠						

	Image Doc. Displayed	PT
70	US 6365768	

East: recombinant adj1 interferon and polymer

	ט	1	Do	cument_ID	Issue Date	Pages	Title	Current OR
1	×		US A	4636383	19870113	6	Interferon-cyclaradine combination	424/85.7
2	×		US A	4710376	19871201	11	Topical therapeutic composition containing oxidation inhibitor system	514/2
3	×	:	US A	4894226	19900116	14	Solubilization of proteins for pharmaceutical compositions using polyproline conjugation	424/85.2
4	⊠		US A	4961969	19901009		Process for recovering microbially produced interferonbeta.	435/69.51
5	⊠		US A	4962091	19901009	14	Controlled release of macromolecular polypeptides	424/85.2
6	×		US A	4966843	19901030		Expression of interferon genes in Chinese hamster ovary cells	435/69.51
7	Ø		US A	5004605	19910402	12	Low pH pharmaceutical compositions of recombinant .betainterferon	424/85.6
8	Ø		US A	5145677	19920908		Process for treatment of diseases	424/85.5

04/02/2002, EAST Version: 1.03.0002

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
1	424/85.4; 435/71.1		Nagabhushan, Tattanahali L. et al.							
2	424/85.4		Evans, Sean A. et al.							
3	424/179.1; 424/85.1; 424/85.4; 424/85.6		Aldwin, Lois et al.							
4	424/85.6; 530/351		Hershenson, Susan et al.							
5	424/130.1; 424/178.1; 424/184.1; 424/193.1; 424/499; 424/85.1; 424/85.6; 514/2; 514/21; 514/964		Eppstein, Deborah A. et al.							
6	435/320.1; 435/360; 435/466; 435/70.1; 435/70.5; 435/70.5; 435/811; 536/23.5; 536/23.52; 536/24.1		McCormick, Francis P. et al.							
7	530/351		Hershenson, Susan et al.							
8	424/85.1; 424/85.2		von Eichborn, Johann-Friedrich et al.							

	I	mage Doc. Displayed	PT
1	US	4636383	
2	US	4710376	
3	ÜS	4894226	
4			
5	US	4962091	
6			
7	US	5004605	
8			

	บ	1	Do	cument_ID	Issue Date	Pages	Title	Current OR
9			US A	5187150	19930216	5	Polyester-based composition for the controlled release of polypeptide medicinal substances	514/2
10	⊠		US A	5324510	19940628		Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma	424/139.1
11	⊠	:     :	US A	5376567	19941227		Expression of interferon genes in Chinese hamster ovary cells	435/320.1
12	×		US A	5382657	19950117	12	Peg-interferon conjugates	530/351
13	⊠		US A	5496266	19960305	14	Device and method of iontophoretic drug delivery	604/20
14	⊠		US A	5539063	19960723	20	Polymer for making poly(ethylene glycol)-protein conjugates	525/403

	T		T			_	1	т	г —	1
	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
9	424/426; 424/457; 424/459; 424/489; 424/490; 424/491; 514/12; 514/15; 514/21; 514/866; 514/886; 514/886; 514/963; 514/965		Speiser, Peter et al.							
10	424/152.1; 424/153.1; 424/154.1; 530/388.22; 530/388.7; 530/388.85; 530/389.6; 530/866; 530/868		Wegner, Craig D. et al.							
11	424/85.4; 435/252.3; 435/358; 435/69.51; 435/91.41; 536/23.52		McCormick, Francis P. et al.							
12	424/85.4; 424/85.7; 530/409; 530/410; 546/300; 546/301; 558/270		Karasiewicz, Robert et al.							
13	604/19		Haak, Ronald P. et al.							
14	546/300		Hakimi, John et al.							

	I	mage Doc. Displayed	PT
9	US	5187150	
10			
11			
12	US	5382657	
13	US	5496266	
14	US	5539063	

	υ	1	Do	cument ID	Issue Date	Pages	Title	Current OR
15	⊠	1 I I	US A	5559213	19960924	19	Polyethylene-protein conjugates	530/351
16	⊠		US A	5593990	19970114		Methods and compositions for inhibition of angiogenesis	514/235.2
17	×		US A	5595732	19970121	21	Polyethylene-protein conjugates	424/85.7
18	×		US A	5632984	19970527	8	Method of treatment of macular degeneration	424/85.4
19	×	:     :	US A	5647844	19970715	13	Device and method of iontophoretic drug delivery	604/20
20	×		US A	5730983	19980324	,	Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma	424/185.1
21	⊠	:     :	US A	5747646	19980505		Polyethylene-protein conjugates	530/351

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
15	424/85.1; 424/85.2; 424/85.4; 424/85.7; 435/188; 530/350; 530/403; 530/405; 530/409		Hakimi, John et al.							
16	514/321; 514/323; 514/417; 514/418; 514/825		D'Amato, Robert							
17	424/85.4; 435/188; 435/964; 514/12; 530/350; 530/403; 530/403; 530/409; 530/816		Hakini, John et al.							
18	424/427; 424/85.7		Wong, Vernon G. et al.							
19	424/449		Haak, Ronald P. et al.							
20	424/143.1; 424/144.1; 424/184.1; 424/198.1; 514/2; 514/8; 530/300; 530/388.22; 530/388.75; 530/395		Wegner, Craig D. et al.							
21	424/85.1; 424/85.2; 424/85.4; 424/85.7; 435/188; 530/350; 530/403; 530/405; 530/409; 564/23		Hakimi, John et al.							

	Image Doc. Displayed	PT
15	US 5559213	
16		
17	US 5595732	
18	US 5632984	
19	US 5647844	
20	·	
21		

	ט	1	Do	cument ID	Issue Date	Pages	Title	Current OR
22	⊠		US A	5792834	19980811		Polyethylene-protein conjugates	530/351
23	⊠		US A	5795779	19980818		Human interferonbeta. (IFNbeta.) produced in Chinese hamster ovary (CHO) cells	435/360
24	⊠		US A	5811119	19980922		Formulation and use of carotenoids in treatment of cancer	424/450
25			US A	5814599	19980929		Transdermal delivery of encapsulated drugs	514/3
26	⊠		US A	5827819	19981027		Covalent polar lipid conjugates with neurologically active compounds for targeting	514/2
27	$\boxtimes$		US A	5834594	19981110		Polyethylene-protein conjugates	530/351
28	×		US A	5849860	19981215		Polyethylene-protein conjugates	528/370
29	×	1 1 3	US A	5857992	19990112	13	Device and method of iontophoretic drug delivery	604/20
30	⊠	1 1 3	US A	5891679	19990406		TNF-alpha muteins and a process for preparing them	435/69.5
31	⊠	4 1 1	US A	5947921	19990907		Chemical and physical enhancers and ultrasound for transdermal drug delivery	604/22

			<del></del>		ī		ı —			
	Current XRef	Retrieval Classif	Inventor	S	С	P	2	3	4	5
22	424/85.4; 424/85.7; 435/188; 530/350; 530/403; 530/409		Hakimi, John et al.							
23	424/85.6; 435/69.51		McCormick, Francis P. et al.							
24			Mehta, Kapil et al.							
25	424/450; 600/309; 600/310; 600/573; 600/574; 604/20; 604/23; 604/304; 604/500; 604/892.1		Mitragotri, Samir S. et al.						,	
26	424/450; 514/649		Yatvin, Milton B. et al.							
27	424/85.4; 424/85.7; 435/188; 530/403; 530/405; 530/409		Hakimi, John et al.							
28	546/300; 546/301		Hakimi, John et al.							
29	607/115		Haak, Ronald P. et al.							
30	424/85.1; 435/252.5; 435/320.1; 530/351; 536/23.5		Lucas, Rudolph et al.							
31	601/2		Johnson, Mark E. et al.							

	Image Doc. Displayed	PT
22		
23		
24		
25		
26		
27		
28		
29	US 5857992	
30		
31		

	ט	1	Do	cument_ID	Issue	Pages	Title	Current OR
32	×			5952451	<b>Date</b> 19990914		Solution polymerization of high molecular weight poly(phosphoesters) in toluene	528/272
33	⊠		US A	5965519	19991012		Covalent polar lipid conjugates with biologically-active compounds for use in salves	514/2
34	×		US A	5972707	19991026		Gene delivery system	435/455
35	⊠		US A	5993435	19991130	13	Device and method of iontophoretic drug delivery	604/501
36	⊠		US A	5994388	19991130		Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis	514/416
37	Ø		US A	6008318	19991228		Two-stage solution polymerization of high molecular weight poly(phosphoesters)	528/398
38	$\boxtimes$		US A	6024977	20000215		Covalent polar lipid conjugates with neurologically active compounds for targeting	424/450
39	×		US A	6025337	20000215		Solid microparticles for gene delivery	514/44
40	×		US A	6028099	20000222		Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization	514/434
41	⊠		US A	6041253	20000321		Effect of electric field and ultrasound for transdermal drug delivery	604/20

	Current	Retrieval		0						
	XRef	Classif	Inventor	S	С	P	2	3	4	5
32			Zhao, Zhong							
33	424/450; 514/51; 514/557; 514/78; 530/300; 530/329; 530/331; 536/26.8; 544/243; 564/153		Yatvin, Milton B. et al.							
34	435/320.1; 435/440; 514/44		Roy, Krishnendu et al.							
35	604/20		Haak, Ronald P. et al.							
36	514/417; 514/418; 514/419; 548/472; 548/473; 548/480; 548/481		Udagawa, Taturo et al.							
37	528/400		Zhao, Zhong et al.							
38	514/2; 514/211.11; 514/217; 514/222.2; 514/223.5; 514/224.8; 514/227.5; 514/649		Yatvin, Milton B. et al.							
39	435/320.1; 435/440; 435/455		Truong, Vu L. et al.							
40	514/456; 514/912		de Juan, Jr., Eugene							
41	600/578; 604/22		Kost, Joseph et al.							

	Image Doc. Displayed	PT
32		
33		
34		
35	US 5993435	
36		
37		
38		
39		
40		
41		

	υ	1	Do	cument ID	Issue Date	Pages	Title	Current OR
42	×		US A	6063759	20000516	35	Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting	514/2
43	⊠		US A	6071948	20000606		Methods and compositions for inhibition of angiogenesis	514/416
44	⊠		US A	6093391	20000725	25	Peptide copolymer compositions	424/85.1
45		:	US A	6114355	20000905	25	Methods and compositions for inhibition of angiogenesis	514/323
46	⊠		US A	6133309	20001017	11	Treatment of T-helper cell type 2-mediated immune disease by retinoid antagonists	514/432
47	⊠		US A	6153212	20001128	19	Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same	424/426
48	⊠		US A	6166173	20001226	39	Biodegradable polymers chain-extended by phosphates, compositions, articles and methods for making and using the same	528/398
49	⊠		US B1	6190315	20010220	15	Sonophoretic enhanced transdermal transport	600/309
50	⊠		US B1	6200597	20010313		Formulation and use of carotenoids in treatment of cancer	424/450

	T			_	I	Г	1	Γ		
	Current XRef	Retrieval Classif	Inventor	S	С	P	2	3	4	5
42	424/450; 435/176; 435/178; 435/179; 435/180; 435/325; 435/366; 530/300; 530/329; 530/331; 530/811; 530/813; 530/815		Yatvin, Milton B. et al.							
43			D'Amato, Robert							
44	424/182.1; 424/78.18; 424/94.3; 514/3; 514/723		Kabanov, Alexander V. et al.							
45			D'Amato, Robert							
46			Bollag, Werner et al.							
47	514/772.3		Mao, Hai-quan et al.							
48	424/426; 424/486; 424/78.37; 523/111; 523/113; 525/538; 528/352; 528/400; 623/924		Mao, Hai-Quan et al.							
49	604/22		Kost, Joseph et al.							
50	514/725		Mehta, Kapil et al.							

	Image Doc. Displayed	PT
42	US 6063759	
43		
44	US 6093391	
45	US 6114355	
46	US 6133309	
47	US 6153212	
48	US 6166173	
49	US 6190315	
50		

	υ	1	De	cument ID	Issue Date	Pages	Title	Current OR
51	⊠		US B1	6200780	20010313	52	Human interferonepsilon.(IF Nepsilon.), a type I interferon	435/69.51
52	×		US B1	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers		424/138.1		
53	×		US B1	6228879	20010508	31	Methods and compositions for inhibition of angiogenesis	514/416
54	Ø		US B1	6234990	20010522	19	Ultrasound enhancement of transdermal transport	604/22
55	⊠		US B1	6235756	20010522		Methods and compositions for inhibition of angiogenesis by thalidomide	514/323
56	×		US B1	6242481	20010605		Methods for the inhibition of angiogenesis with arglabin	514/468
57			US B1	6264990	20010724		Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity.	424/499

	Current	Retrieval						Γ		
	XRef	Classif	Inventor	S	С	P	2	3	4	5
51	424/85.4; 435/252.3; 435/252.33; 435/254.2; 435/320.1; 435/325; 435/358; 530/351; 536/23.52		Chen, Jian et al.							
52	424/141.1; 424/142.1; 424/155.1; 530/387.7; 530/388.8; 530/391.1; 530/391.3; 530/391.7		Dan, Michael D. et al.							
53			Green, Shawn J. et al.							
54			Rowe, Stephen et al.							
55			D'Amato, Robert							
56	514/473; 514/475		Udagawa, Taturo et al.							
57	424/489; 514/2		Knepp, Victoria Marie et al.							

		mage Doc. Displayed	PT
51	US	6200780	
52	US	6207153	
53	US	6228879	
54	US	6234990	
55			
56			
57			

	U	1	Do	cument_ID	Issue Date	Pages	Title	Current OR
58	⊠		US B1	6274635	20010814		Alkylated resorcinol derivatives for the treatment of immune diseases	514/718
59	⊠		US B1	6277410	20010821	29	Copolymer compositions for oral delivery	424/486
60	⊠		US B1	6277830	20010821	13	5'-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon	514/43
61	$\boxtimes$		US B1	6299869	20011009	50	Human interferon-epsilon: a type I interferon	424/85.4
62			US B1	6299877	20011009		Type I interferons	424/158.1

	Current	Retrieval						Γ		
	XRef	Classif	Inventor	s	С	P	2	3	4	5
58	514/454; 514/456; 514/720; 514/731; 568/626; 568/630; 568/650; 568/651; 568/652; 568/658; 568/662; 568/716		Travis, Craig A.							
59	424/422; 514/772.1; 514/772.3		Kabanov, Alexander V. et al.							
60	424/85.4; 424/85.7; 514/2; 514/21; 514/894; 530/351		Ganguly, Ashit K. et al.							
61	435/252.33; 435/320.1; 435/325; 435/358; 435/69.1; 435/69.2; 435/69.51; 514/12; 514/2; 530/350; 530/351; 536/23.1; 536/23.52		Chen, Jian et al.							
62	424/139.1; 424/145.1; 530/351; 530/387.9; 530/388.1; 530/388.23 ; 530/389.1		Chen, Jian et al.							

	Image Doc. Displayed	PT
58		
59	US 6277410	
60	US 6277830	
61	US 6299869	
62		

	υ	1	Document_ID	Issue Date	Pages	Title	Current OR
63			US 6300475 B1	20011009		Interferon PRO655	530/351
64	×		US 6312924 B1	20011106	44	Murine interferonalpha.	435/69.51
65	⊠		US 6322797 B1 .	20011127	40	Biodegradable terephthalate polyester-poly (phosphate) polymers, compositions, articles, and methods for making and using the same	424/78.37
66	⊠		US 6326397 B1	20011204	24	Retinoid antagonists and use thereof	514/531
67	⊠		US 6329175 B1	20011211	59	Interferonepsilon.	435/69.51

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
63	435/252.3; 435/252.33; 435/254.11; 435/254.2; 435/320.1; 435/325; 435/325; 435/358; 435/69.51; 530/350; 536/23.1; 536/23.5; 536/23.52		Chen, Jian et al.							
64	435/252.8; 435/254.11; 435/320.1; 435/325; 435/348; 435/349; 435/419; 435/70.5; 514/2; 530/351; 536/23.1; 536/23.52		Presnell, Scott R. et al.							
65	428/378; 442/248; 523/115; 528/398		Mao, Hai-Quan et al.							
66	514/502; 514/570; 554/218; 560/55; 560/59; 562/465; 562/469; 568/442		Bollag, Werner et al.							
67	435/252.3; 435/254.1; 435/255.1; 435/320.1; 435/325; 435/348; 435/349; 435/410; 530/351; 536/23.52		Conklin, Darrell C. et al.							

	Image Doc. Displayed	PT
63		
64	US 6312924	
65	US 6322797	
66	US 6326397	
67	US 6329175	

	บ	1	Doc	cument ID	Issue Date	Pages	Title	Current OR
68	⊠	:     :	US B1	6339060	20020115	35	Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting	514/2
69			US B1	6362162	20020326	7	CML Therapy	514/2

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
68	424/450; 435/176; 435/178; 435/179; 435/325; 435/325; 435/366; 530/300; 530/329; 530/331; 530/811; 530/813; 530/815		Yatvin, Milton B. et al.							
69			Rybak, Mary Ellen et al.	⊠						

		mage Doc. Displayed	PT
68	US	6339060	
69	US	6362162	

East: interferon & polymer?

	ט	1	Do	cument ID	Issue Date	Pages	Title	Current	OR
1			CN A	1316436	20011010	NA	Process for preparing water-soluble slow-releasing recombination protein		
2			DD	275692 A	19900131	NA	Semi-plastic products redn. from poly-inosinic acid - and complementary nucleotide, useful as stable interferon inducers and killer cell activators		
3			DD	97428 A	N/A	NA	N-vinyl-nucleobase polymers - with biological activity		
4	×		DE A	2359621	19750605	9	Antiviral mainly isotactic polyacrylic acid salts - prepd. by low temp. polymn. of branched-chain alkyl acrylates then saponification		
5	⊠		DE A	3603444	19870806		Stabilised topical interferon alpha formulations - contain combination of e.g. cellulose derivs., gelatin and antiadhesion agent as stabiliser and carrier		
6	×		DE G	3779221	20001122		Device administering dose of polypeptide into lungs - delivers suspension in gas of particles sized to penetrate into alveoli		
7	⊠		DE C	3790487	19990331		Therapeutic agent encapsulated in proteinoid microspheres - for oral admin. to protect agent against gastrointestinal tract deactivation		
8	⊠		DE A	3822406	19890112		Low molecular double-stranded rna prodn by calibration of single-strand ed nucleic acid polymers before annealing to give double-stranded product		

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
1			CHEN, H et al.	×						
2			GOTTSETEIN, H et al.	×						
3				⊠						
4										
5			FRANZ, H							
6			DAUGHERTY, A L							
7		•	ROSEN, R et al.							
8			JUNICHI, Y et al.							

	Image Doc. Displayed	PT
1		
2		
3		
4	US 4150238	
5		
6		
7		
8		

	σ	1	Do	cument ID	Issue Date	Pages	Title	Current	OR
9	×		DE G	3873712	19991110		Slow release compsn. for treating eye conditions - comprises drug microencapsulated in liposome or polymer		
10	×		DE A	4406172	20000816		Branched polyester used as biodegradable depot matrix - prepd. from electrolyte-substd. poly:ol and poly-hydroxy-carboxylic acid, esp. for supplying peptide or protein, e.g. interleukin		
11	⊠		ΕP	138216 B	19850508		Sustained release injectable compsn consists of bio-degradable powder contg. the active ingredient suspended in viscous liq.		
12	⊠		ΕP	180567 A	19860507		Sepn. of poly:peptide fractions from soln by pptn. of one fraction with soluble charged polymer in presence of soluble neutral polymer for enhanced efficacy		
13	⊠		EP	197776 A	19861015		Prepn. of porous oxide or hydroxide bodies - by adding sol. of the oxide or hydroxide to fluid freezing medium then heating		
14			ΕP	36372 A	19810923		Partially deacylated N-acyl ganglioside(s) and glyco:lipid(s) - have free amine groups which may be used to couple to solid supports without loss of specific affinity		
15	⊠		EΡ	377477 A	19900711		Micro-encapsulation of bioactive substances by phase-sepn comprises dispersing substance in organic soln. of biocompatible polymer, adding phase separator and excess hardening agent		

	Retrieval Classif	Inventor	s	С	P	2	3	4	5
9		WONG, V G							
10		KISSEL, T et al.							
11		FUJIOKA, K et al.							
12		HO, S V							
13		PEPPER, D S							
14		COURT, G et al.							
15		GROENENDAAL, J W et al.							

	Image Doc. Displayed	PT
9		
10		
11		
12		
13		
14		
15		

	ט	1	Do	cument ID	Issue Date	Pages	Title	Current	OR
16			EP	404062 A	19901227		New 2-oxy:germyl ethane sulphonate and sulphonamide polymers - useful as immunomodulators, interferon-prodn. enhancers and anti-tumour agents, and for treatment of AIDS		
17	⊠		ΕP	572942 A	20001129		Delayed release oral pharmaceutical compsn. for specific colon delivery - comprises core contg. active principles, intermediate swellable polymer coating delaying release and outer layer whose removal activates intermediate layer removal		
18	⊠		ΕP	58481 A	19820825		Compsn. of poly:lactide and acid stable poly:peptide - for use in aq. environment to release all polypeptide continuously		
19	×		EP	652223 A	19951011		New 3-oxy:germyl:propionic acid polymer - useful in treatment of, e.g., immune diseases caused by viruses		
20	⊠		ΕP	733067 B	20011206		N-terminally chemically modified proteins - partic. G-CSF or consensus interferon modified with polymers, esp. polyethylene glycol		
21	×		EP	978289 A	20000221		New virucide drug, especially for treating influenza contains iodine and lithium chloride		
22	⊠		FR A	2279422	19760326		Antiviral interferon fixed to polysaccharide support - act on exterior of cells without effecting pathological processes inside cell		

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
16			BABA, Y et al.							
17		•	BUSETTI, C et al.							
18			HUTCHINSON, F G							
19			MITANI, T et al.							
20			DEPRINCE, R B et al.							
21			ARAKELJAN, N G et al.							
22										

	Image Doc. Displayed	PT
16		
17		
18		
19		
20		
21		
22		

	T		Ι		Issue	I		i	
	Ū	1	Do	cument ID	Date	Pages	Title	Current	OR
23			GB B	2317340	19991214		Compsn. for delivery of active agent - has polymeric lamellar substrate particles at least in part crystalline, with adsorbed agent		
24			JP A	03251599	19911111		Interferon-beta prodn. augmenting substances - are sugar-protein polymers used to treat infections caused by viruses, bacteria and fungi		
25	⊠		JP A	05058877	20010709		Nasal drop or spray having high absorption - contains bioactive substance, sucrose fatty acid ester, and carbory-vinyl! polymer		
26			JP A	63196276	19880815		Base used in cell cultivation for prodn. of e.g. vaccine, etc comprise polymer base with micro phase separative structure and laminated with monomolecular layer		
27	×		JP A	63196277	19880815		Base for cell culture with adhesive properties - comprises porous or hollow fibrous high mol. wt. polymer with ozone-treated surface supporting e.g. sugar or protein		
28			JP A	63196278	19880815		Base for cultivation of cells - comprises hollow or porous fibres of high mol. wt. polymer with surface treated and supporting fibrin stripe, lattice etc.		
29	⊠		JP A	63196279	19880815		Base for cell culture - comprises porous or hollow fibre high mol. wt. polymer supporting laminin glyco:protein		

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
23			COOMBES, A G A et al.							
24										
25										
26										
27										
28										
29										

_	Image Doc. Displayed	PT
23		
24		
25		
26		
27		
28	1	
29		

	บ	1	Doct	ment_ID	Issue Date	Pages	Title	Current	OR
30	×		JP 6	3196281	19880815		Base for cell culture - comprises complex of high mol. wt. polymer with inorganic substance		
31			US 2001 A	.0007758	20020205		Suppressing an autoimmune reaction in multiple sclerosis patients		
32			US 2001 A	.0046487	20011129		Method of permeabilizing platelets useful for drug delivery involves treating isolated platelets with an acid		
33	×		US 3 A	884845	19750520		Condensn polymers of polyethylenimine and pentachloropyridine - as interferon inducer and antiviral agent		
34	×		US 4 A	189534	19800219		Cell culture microcarriers		
35	Ø		US 4 A	293654	19811006		Cell culture microcarriers		
36	⊠		US 4	710376	19871201		Stable topical compsn. contg. lymphokine - contains water soluble polymers one with reducing moieties and another with oxidising moieties covalently bound and aq. vehicle		
37	×		US 5	004605	19910402		Low pH pharmaceutical compositions of recombinant beta -interferon		
38	⊠		US 5 A	256570	19931026		Rotary biological contactor with supports enveloped in chamber - configured to support microorganisms or cells, pref. corrugated sheet media with drain holes rotatable in outer jacket		
39	⊠		US 5	334379	19940802		Immunogenic conjugates of bacterial capsular polymers - linked to interferon or interleukin, useful in vaccines against bacterial infection		

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
30										
31			MARON, R et al.							
32			ROSER, B J et al.							
33										
34			LEVINE, DAVID W et al.							
35			LEVINE, DAVID W et al.							
36			EVANS, S A et al.							
37			HERSHENSON, SUSAN et al.							
38			CLYDE, R A							
39			EBY, R et al.							

	Image Doc. Displayed	PT
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		

	ט	1	Do	cument_ID	Issue Date	Pages	Title	Current	OR
40	⊠		US A	5449720	19991020		New polymer complexes of biologically active peptide(s) or proteins - are used to amplify delivery of the active agent using the vitamin B12 uptake system		
41			US A	5681811	19970213		Bioactive agent conjugates with hydrophilic or lipophilic polymers - having improved stability to degradation and passage through membranes, used with proteins, peptide(s), e.g., insulin, nucleotide(s), antibiotics, etc.		
42	×		US A	5714166	19980203		Conjugates of dense star polymers - with therapeutic agents, diagnostic agents, agrochemicals, etc.		
43			US A	5824784	19981020	30	N-terminally chemically modified protein compositions and methods		
44	⊠		US A	6048736	20000411		Controlled release, targetable composition comprises the active agent, nucleic acid or toxin entrapped in a cyclodextrin polymer		
45	×		US B	6221351	20020115		Use of staphylococcal enterotoxin(s) and homologues - for treating cancer in a patient or for the treatment of auto-immune diseases		
46	⊠		US B	6342244	20011219		New hydrophilic polymers derivatized through a dithiobenzyl linkage to an amine-containing ligand such as polypeptide, lipid or drug, e.g. interferon, interleukin, growth factor or enzyme		

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
40			GOULD, A R et al.							
41			EKWURIBE, N N							
42			BAKER, J R et al.							
43			KINSTLER, OLAF B et al.	⊠						
44			KOSAK, K M							
45			TERMAN, D S et al.							
46			ZALIPSKY, S et al.							

	Image Doc. Displayed	PT
40		
41		
42		
43	US 5824784	
44		
45		
46		

	ט	1	Document_ID	Issue Date	Pages	Title	Current	OR
47			WO 200121229 A	20010329		Endovascular stents comprise stent material, antimicrobial agent and optional antiinflammatory agent, provide immediate mechanical support to maintain vessel patency and slowly release active agents		
48	⊠		WO 200141810 A	20010614		Nucleic acid delivery system which includes polymeric carrier particles which are electrically neutral and insoluble in body fluids, can achieve rapid release of nucleic acid into cells		
49	⊠		WO 9216555 A	19921001		Polypeptide(s) or glyco-polypeptide(s) conjugated to water-soluble polymers - contain hydrazine or hydrazone gp. and peptide that prevents crosslinking, preserving activity		
50	⊠	! I I	WO 9405332 A	19940317		New glycolated, glycosylated macromolecule derivs esp. polypeptide(s), having reduced immunogenicity without redn. of biological activity		
51	⊠		WO 9513090 A	19950518		Long-acting alpha-interferon polymer conjugates - prepd. in presence of surfactant for higher yield and activity, used e.g. as antiviral agents		·
52	Ø		WO 9611953 A1	19960425		N-TERMINALLY CHEMICALLY MODIFIED PROTEIN COMPOSITIONS AND METHODS		

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
47			LEE, C C							
48			GUAN, H							
49			LEE, C et al.							
50			MTIMKULU, T							
51			CHO, M et al.							
52			KINSTLER, OLAF B et al.							

	Image Doc. Displayed	PT
47		
48		
49		
50		
51		
52		

	υ	1	Document ID	Issue Date	Pages	Title	Current OR
53	$\boxtimes$	: I I	WO 9961032 A	20010525		Production of homogeneous and safe nucleic acid-containing composite preparation, with good quality, no coarse particles and capable of filtrative sterilization	

04/02/2002, EAST Version: 1.03.0002

f	Current XRef	Retrieval Classif	Inventor	S	С	P	2	3	4	5
53			HIRABAYASHI, K et al.							

	Image Doc. Displayed	PT
53		

East: recombinant and interferon and polymer

7	υ	1	Do	cument ID	Issue Date	Pages	Title	Current OR
1	×		US A	4710376	19871201	11	Topical therapeutic composition containing oxidation inhibitor system	514/2
2	×		US A	4894226	19900116		Solubilization of proteins for pharmaceutical compositions using polyproline conjugation	424/85.2
3	⊠		US. A	4962091	19901009		Controlled release of macromolecular polypeptides	424/85.2
4	⊠		US A	5004605	19910402	•	Low pH pharmaceutical compositions of recombinant .betainterferon	424/85.6
5	⊠		US A	5183746	19930202		Formulation processes for pharmaceutical compositions of recombinant .beta	435/69.51
6	×		US A	5187150	19930216		Polyester-based composition for the controlled release of polypeptide medicinal substances	514/2
7	⊠		US A	5196323	19930323		Process for preparing and purifying alpha-interferon	435/69.51

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
1	424/85.4		Evans, Sean A. et al.							
2	424/179.1; 424/85.1; 424/85.4; 424/85.6		Aldwin, Lois et al.							
3	424/130.1; 424/178.1; 424/184.1; 424/193.1; 424/499; 424/85.1; 424/85.4; 424/85.6; 514/2; 514/21; 514/964		Eppstein, Deborah A. et al.							
4	530/351		Hershenson, Susan et al.							
5	424/85.6; 530/351		Shaked, Ze'Ev et al.							
6	424/426; 424/457; 424/459; 424/489; 424/490; 424/491; 514/12; 514/15; 514/21; 514/866; 514/886; 514/886; 514/963; 514/965		Speiser, Peter et al.							
7	424/85.4; 424/85.7; 435/252.3; 530/351; 530/413; 530/416; 530/419		Bodo, Gerhard et al.							

	Image Doc. Displayed	PT
1		
2		
3		
4		
5		
6		
7		

	บ	1	De	cument ID	Issue Date	Pages	Title	Current OR
8	×		US A	5248769	19930928		Process for recovering refractile bodies containing heterologous proteins from microbial hosts	530/414
9		:	US A	5286637	19940215		Biologically active drug polymer derivatives and method for preparing same	435/183
10	⊠		US A	5310729	19940510		Interferon-related polypeptides as CR2 ligands and their use for modulating immune cell functions	514/15
11	⊠	;	US A	5382657	19950117	•	Peg-interferon conjugates	530/351
12	⊠		US A	5496266	19960305		Device and method of iontophoretic drug delivery	604/20
13	⊠		US A	5508031	19960416		Method for treating biological damage using a free-radial scavenger and interleukin-2	424/85.2
14	⊠		US A	5539063	19960723		Polymer for making poly(ethylene glycol)-protein conjugates	525/403
15	⊠		US A	5540923	19960730		Interferon proteins	424/85.5
16	⊠		US A	5559213	19960924		Polyethylene-protein conjugates	530/351

				_			_	т		
	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
8	435/69.1; 435/69.5; 435/69.51; 435/69.52; 530/351; 530/412; 530/427		Dorin, Glenn							
9	424/85.2; 424/94.4; 435/181; 435/189; 435/68.1; 435/832; 514/2; 530/397; 530/399		Veronese, Francesco et al.							
10	514/16; 530/327; 530/328		Lernhardt, Waldemar							
11	424/85.4; 424/85.7; 530/409; 530/410; 546/300; 546/301; 558/270		Karasiewicz, Robert et al.							
12	604/19		Haak, Ronald P. et al.							
13	530/351		Zimmerman, Robert et al.							
14	546/300		Hakimi, John et al.							
15	424/85.4; 424/85.6; 530/351		Ebbesen, Peter et al.							
16	424/85.1; 424/85.2; 424/85.4; 424/85.7; 435/188; 530/350; 530/403; 530/405; 530/409		Hakimi, John et al.							

	Image Doc. Displayed	PT
8		
9		
10		
11		
12		
13		
14		
15		
16		

		,						
!	ט	1	Do	cument_ID	Issue Date	Pages	Title	Current OR
17			US A	5595732	19970121		Polyethylene-protein conjugates	424/85.7
18			US A	5614504	19970325		Method of making inosine monophosphate derivatives and immunopotentiating uses thereof	514/45
19	Ø		US A	5632983	19970527		Method for treating secondary immunodeficiency	424/85.1
20	⊠		US A	5632984	19970527		Method of treatment of macular degeneration	424/85.4
21	×		US A	5647844	19970715		Device and method of iontophoretic drug delivery	604/20
22	×		US A	5658565	19970819		Inducible nitric oxide synthase gene for treatment of disease	424/93.21
23	×		US A	5667776	19970916		Treatment for biological damage using tumor necrosis factor and a free-radical scavenger	424/85.1
24	⊠		US A	5698194	19971216		Method for making a medicament for treating secondary immunodeficiency	424/85.1
25	×		US A	5702697	19971230		Treatment for biological damage using a colony stimulating factor and a biological modifier	424/85.1
26	⊠		US A	5736154	19980407		Transdermal delivery system	424/449

						,	т —			
	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
17	424/85.4; 435/188; 435/964; 514/12; 530/350; 530/403; 530/405; 530/409; 530/816		Hakini, John et al.							
18	536/26.7; 536/27.8		Hadden, John W. et al.							
19	424/85.2; 424/85.4; 514/21		Hadden, John W.							
20	424/427; 424/85.7	,	Wong, Vernon G. et al.							
21	424/449		Haak, Ronald P. et al.							
22	424/93.1; 424/93.2; 435/189; 435/191; 435/235.1; 435/320.1; 514/44; 536/23.1; 536/23.2; 536/23.5		Billiar, Timothy R. et al.							
23	514/2; 514/263.31 ; 514/474; 514/550; 530/351		Zimmerman, Robert et al.							
24	424/85.2; 424/85.4; 424/85.5; 435/70.4; 435/70.5		Hadden, John Winthrop							
25	514/2; 514/8; 514/885; 530/351		Zimmerman, Robert et al.							
26	424/448		Fuisz, Richard C.							

	Image Doc. Displayed	PT
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		

	U	1	Do	cument ID	Issue Date	Pages	Title	Current OR
27			US A	5747646	19980505		Polyethylene-protein conjugates	530/351
28			US A	5756353	19980526		Expression of cloned genes in the lung by aerosol-and liposome-based delivery	514/44
29	⊠		US A	5762920	19980609		Megakaryocyte production	424/85.1
30		: 1 1	US A	5792834	19980811		Polyethylene-protein conjugates	530/351
31	⊠		US A	5814599	19980929		Transdermal delivery of encapsulated drugs	514/3
32	⊠		US A	5827819	19981027		Covalent polar lipid conjugates with neurologically active compounds for targeting	514/2
33	⊠		US A	5834594	19981110		Polyethylene-protein conjugates	530/351

		Retrieval Classif	Inventor	S	С	P	2	3	4	5
27	XRef 424/85.1; 424/85.2; 424/85.4; 424/85.7; 435/188; 530/350; 530/403; 530/405; 530/409; 564/23	Classif	Hakimi, John et al.							
28	128/200.14; 424/450; 435/320.1; 435/375; 435/377; 435/458; 435/459; 435/6; 435/6; 435/69.1; 435/91.1; 536/24.1		Debs, Robert J.							
29	424/85.2		Yung, Yee Pang et al.							
30	424/85.4; 424/85.7; 435/188; 530/350; 530/403; 530/405; 530/409		Hakimi, John et al.							
31	424/450; 600/309; 600/310; 600/573; 600/574; 604/20; 604/23; 604/304; 604/500; 604/892.1		Mitragotri, Samir S. et al.							
32	424/450; 514/649		Yatvin, Milton B. et al.							
33	424/85.4; 424/85.7; 435/188; 530/403; 530/405; 530/409		Hakimi, John et al.							

	Image Doc. Displayed	PT
27		
28		
29		
30		
31		
32		
33		

		,	T			,		<del></del>
	ט	1	Do	cument ID	Issue Date	Pages	Title	Current OR
34	×		US A	5849800	19981215		Use of amantadine for treatment of Hepatitis	514/647
35	×		US A	5849860	19981215		Polyethylene-protein conjugates	528/370
36	×		US A	5857992	19990112		Device and method of iontophoretic drug delivery	604/20
37	⊠		US A	5947921	19990907		Chemical and physical enhancers and ultrasound for transdermal drug delivery	604/22
38	×		US A	5952451	19990914		Solution polymerization of high molecular weight poly(phosphoesters) in toluene	528/272
39			US A	5965519	19991012		Covalent polar lipid conjugates with biologically-active compounds for use in salves	514/2
40	×		US A	5972707	19991026		Gene delivery system	435/455
41	Ø		US A	5993435	19991130		Device and method of iontophoretic drug delivery	604/501
42	×	:     :	US A	5994388	19991130		Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis	514/416
43	⊠	! I I :	US A	6002961	19991214		Transdermal protein delivery using low-frequency sonophoresis	604/20
44	⊠	;     ;	US A	6008318	19991228		Two-stage solution polymerization of high molecular weight poly(phosphoesters)	528/398

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
34			Smith, Jill P.							
35	546/300; 546/301		Hakimi, John et al.							
36	607/115		Haak, Ronald P. et al.							
37	601/2		Johnson, Mark E. et al.							
38			Zhao, Zhong							
39	424/450; 514/51; 514/557; 514/78; 530/300; 530/329; 530/331; 536/26.8; 544/243; 564/153		Yatvin, Milton B. et al.							
40	435/320.1; 435/440; 514/44		Roy, Krishnendu et al.							
41	604/20		Haak, Ronald P. et al.							
42	514/417; 514/418; 514/419; 548/472; 548/473; 548/480; 548/481		Udagawa, Taturo et al.							
43	424/448; 424/449; 604/2		Mitragotri, Samir S. et al.							
44	528/400		Zhao, Zhong et al.							

	Image Doc.	PT
	Displayed	
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		

	U	1	Do	cument ID	Issue Date	Pages	Title	Current OR
45	⊠		US A	6018678	20000125		Transdermal protein delivery or measurement using low-frequency sonophoresis	604/20
46	⊠		US A	6020144	20000201		Sustained delivery device comprising a Leishmania protozoa and methods of making and using the same	435/7.22
47	×		US A	6024977	20000215		Covalent polar lipid conjugates with neurologically active compounds for targeting	424/450
48	×		US A	6025337	20000215		Solid microparticles for gene delivery	514/44
49	×		US A	6028099	20000222		Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization	514/434
50	⊠		US A	6041253	20000321		Effect of electric field and ultrasound for transdermal drug delivery	604/20
51	$\boxtimes$		US A	6063759	20000516	35	Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting	514/2
52	×		US A	6093391	20000725	25	Peptide copolymer compositions	424/85.1

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
45	604/22		Mitragotri, Samir S. et al.							
46	424/269.1; 424/94.3; 435/245; 435/258.3; 435/91.41; 435/91.42		Gueiros-Filho, Frederico J. et al.							
47	514/2; 514/211.11; 514/217; 514/222.2; 514/223.5; 514/224.8; 514/227.5; 514/649		Yatvin, Milton B. et al.							
48	435/320.1; 435/440; 435/455		Truong, Vu L. et al.							
49	514/456; 514/912		de Juan, Jr., Eugene							
50	600/578; 604/22		Kost, Joseph et al.							
51	424/450; 435/176; 435/178; 435/179; 435/180; 435/325; 435/366; 530/300; 530/329; 530/331; 530/811; 530/813; 530/815		Yatvin, Milton B. et al.							
52	424/182.1; 424/78.18; 424/94.3; 514/3; 514/723		Kabanov, Alexander V. et al.							

	Image Doc. Displayed	PT
45		
46		
47		
48		
49		
50		
51	US 6063759	
52	us 6093391	

	ט	1	Do	cument ID	Issue Date	Pages	Title	Current OR
53			US A	6114355	20000905	25	Methods and compositions for inhibition of angiogenesis	514/323
54			US A	6153212	20001128	19	Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same	424/426
55			US A	6166173	20001226	39	Biodegradable polymers chain-extended by phosphates, compositions, articles and methods for making and using the same	528/398
56			US B1	6187993	20010213	34	Transgenic animals as model of psoriasis	800/18
57	⊠		US B1	6190315	20010220	15	Sonophoretic enhanced transdermal transport	600/309
58	⊠		US B1	6200780	20010313	52	Human interferonepsilon.(IF Nepsilon.), a type I interferon	435/69.51
59	×		US B1	6207153	20010327	56	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers	424/138.1
60	⊠		US B1	6214804	20010410	37	Induction of a protective immune response in a mammal by injecting a DNA sequence	514/44

	Current	Retrieval	Inventor	s	С	P	2	3	4	5
	XRef	Classif					_		<u> </u>	
53			D'Amato, Robert							
54	514/772.3		Mao, Hai-quan et al.							
55	424/426; 424/486; 424/78.37; 523/111; 523/113; 525/538; 528/352; 528/400; 623/924		Mao, Hai-Quan et al.							
56	435/325; 800/21; 800/22; 800/25; 800/3		Watt, Fiona M. et al.							
57	604/22		Kost, Joseph et al.							
58	424/85.4; 435/252.3; 435/252.33; 435/254.2; 435/320.1; 435/325; 435/325; 435/358; 530/351; 536/23.52		Chen, Jian et al.							
59	424/141.1; 424/142.1; 424/155.1; 530/387.7; 530/388.8; 530/391.1; 530/391.3; 530/391.7		Dan, Michael D. et al.							
60	435/455; 435/69.1		Felgner, Philip L. et al.							

	I	mage Doc. Displayed	PT
53	US	6114355	
54	US	6153212	
55	US	6166173	
56	US	6187993	
57	US	6190315	
58	US	6200780	
59	US	6207153	
60	US	6214804	

	ט	1	Do	cument_ID	Issue Date	Pages	Title	Current OR
61			US B1	6228844	20010508	42	Stimulating vascular growth by administration of DNA sequences encoding VEGF	514/44
62	⊠		US B1	6228879	20010508	31	Methods and compositions for inhibition of angiogenesis	514/416
63	Ø		US B1	6234990	20010522	19	Ultrasound enhancement of transdermal transport	604/22
64	Ø		US B1	6277410	20010821	29	Copolymer compositions for oral delivery	424/486
65	×		US B1	6277830	20010821	13	5'-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon	514/43
66			US B1	6284473	20010904	39	P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status	435/7.1
67	×		US B1	6299869	20011009	50	Human interferon-epsilon: a type I interferon	424/85.4
68	☒		US B1	6303344	20011016	68	Methods and compositions for polypeptide engineering	435/91.1

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
61	435/455		Wolff, Jon A. et al.							
62			Green, Shawn J. et al.							
63			Rowe, Stephen et al.							
64	424/422; 514/772.1; 514/772.3		Kabanov, Alexander V. et al.							
65	424/85.4; 424/85.7; 514/2; 514/21; 514/894; 530/351		Ganguly, Ashit K. et al.							
66	436/501; 436/504; 436/536; 436/540; 436/542; 436/804; 436/811		Whitaker, John Nicholas et al.							
67	435/252.33; 435/320.1; 435/325; 435/358; 435/69.1; 435/69.2; 435/69.51; 514/12; 514/12; 530/350; 530/351; 536/23.1; 536/23.52		Chen, Jian et al.							
68	435/252.3; 435/325; 435/6; 435/91.5; 536/23.1		Patten, Phillip A. et al.							

	I	mage Doc. Displayed	PT
61	US	6228844	
62	US	6228879	
63	US	6234990	
64	US	6277410	
65	US	6277830	
66	lUS	6284473	
67	US	6299869	
68	US	6303344	

	บ	1	Document ID	Issue Date	Pages	Title	Current OR
69			US 6312924 B1	20011106	44	Murine interferonalpha.	435/69.51
70	⊠		US 6319713 B1	20011120	72	Methods and compositions for polypeptide engineering	435/440
71	⊠		US 6322797 B1	20011127	40	Biodegradable terephthalate polyester-poly (phosphate) polymers, compositions, articles, and methods for making and using the same	424/78.37
72	×		US 6329175 B1	20011211	59	Interferonepsilon.	435/69.51
73	⊠		US 6335160 B1	2002010i	71	Methods and compositions for polypeptide engineering	435/6

Γ.	Commont	Dodon onel	I			I	f	T	T	Γ
	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
69	435/252.8; 435/254.11; 435/320.1; 435/325; 435/348; 435/349; 435/419; 435/70.5; 514/2; 530/351; 536/23.1; 536/23.52		Presnell, Scott R. et al.							
70	435/6; 435/91.2; 536/23.1; 536/24.3		Patten, Phillip A. et al.							
71	428/378; 442/248; 523/115; 528/398		Mao, Hai-Quan et al.							
72	435/252.3; 435/254.1; 435/255.1; 435/320.1; 435/325; 435/348; 435/349; 435/410; 530/351; 536/23.52		Conklin, Darrell C. et al.							
73	435/320.1; 435/440; 435/471; 435/69.1; 435/91.2; 536/23.1; 536/24.3; 536/24.33		Patten, Phillip A. et al.							

	I	mage Doc. Displayed	PT
69	US	6312924	
70	US	6319713	
71	US	6322797	
72	US	6329175	
73	US	6335160	

	บ	1	Dec	cument ID	Issue Date	Pages	Title	Current	OR
74	$\boxtimes$		US B1	6339060	20020115	35	Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting	514/2	
75	⊠		US B1	6355484	20020312	71	Methods and compositions for polypeptides engineering	435/440	
76			US B1	6362162	20020326	7	CML Therapy	514/2	

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	თ	4	5
74	424/450; 435/176; 435/178; 435/179; 435/180; 435/325; 435/366; 530/300; 530/329; 530/331; 530/811; 530/813; 530/815		Yatvin, Milton B. et al.							
75	435/6; 536/23.1; 536/24.3		Patten, Phillip A. et al.							
76			Rybak, Mary Ellen et al.	Ø						

		mage Doc. Displayed	PT
74	US	6339060	
75	US	6355484	
76	US	6362162	

East, Text secon: interferon and intra nasa Judj 1 erop?

			Ces	l, lext s		ter feron	and Intra hasa gard 1	1
	Ū	1	Do	cument ID	Issue Date	Pages	Title	Current OR
1			US A	5240694	19930831	13	Combined antiviral and antimediator treatment of common colds	424/45
2	⋈		US A	5422097	19950606	13	Combined antiviral and antimediator treatment of common colds	424/45
3			US A	5474983	19951212	16	Method of inhibiting pro-inflammatory mediator release from basophils and mast cells	514/12
4			US A	5492689	19960220	14	Combined virustatic antimediator (COVAM) treatment of common colds	424/45
5	×		US A	5728680	19980317	92	Methods for normalizing numbers of lymphocytes	514/19
6	×		US A	5770576	19980623	87	Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity	514/19
7	⊠		US A	5807830	19980915	89	Method for treatment of purulent inflammatory diseases	514/19
8	⊠		US A	5811399	19980922	99	Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants	514/19
9	⊠		US A	6100386	20000808	28	Human gene/protein involved in chronic myelogenous leukemia	536/23.1

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
1	424/405; 424/408; 424/434; 424/435; 424/451; 424/464; 424/489		Gwaltney, Jr., Jack M.	×						
2	424/405; 424/408		Gwaltney, Jr., Jack M.							
3	514/21		Kuna, Piotr et al.	×						
4	424/405; 424/408; 424/434; 424/435; 424/451; 424/464; 424/489; 604/291		Gwaltney, Jr., Jack M.	⊠						
5	514/11; 514/9		Morozov, Vyacheslav G. et al.							
6	514/11		Morozov, Vyacheslav G. et al.							
7	424/184.1; 424/185.1; 424/278.1; 514/15; 514/16; 514/17; 514/18		Morozov, Vyacheslav G. et al.						· 🗆	
8	514/11		Khavinson, Vladimir Kh. et al.					·		
9	435/320.1; 435/325; 435/69.1; 435/71.1; 536/22.1; 536/23.5		Carpino, Nicholas A. et al.						Ο.	

	I	mage Doc. Displayed	PT
1	US	5240694	
2	US	5422097	
3	US	5474983	
4	US	5492689	
5	US	5728680	
6	US	5770576	
7	US	5807830	
8	US	5811399	
9	US	6100386	

	U	1	Do	cument ID	Issue Date	Pages	Title	Current	OR
10	×		US A	6140064	20001031	32	Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3	435/7.2	
11			US A	6165476	20001226	19	Fusion proteins with an immunoglobulin hinge region linker	424/195.	11
12	⊠		US B1	6184358	20010206	50	IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor	530/388.	22
13	$\boxtimes$		US B1	6329159	20011211	44	Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function	435/7.24	
14			US B1	6329510	20011211	35	Anti-CCR1 antibodies and methods of use therefor	530/388.	22

									,	
	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
10	435/325; 435/7.1; 530/350; 530/351; 530/387.9		Loetscher, Marcel et al.							
11	424/85.2; 435/252.3; 435/320.1; 435/325; 435/69.7; 530/351; 530/387.3; 530/399; 536/23.4		Strom, Terry B. et al.							
12	435/326; 435/7.1; 530/387.1; 530/387.9; 530/388.1		Loetscher, Marcel et al.							
13	424/133.1; 424/139.1; 424/143.1; 435/328; 435/331; 435/334; 435/810; 435/975; 530/387.3; 530/387.9; 530/388.22; 530/389.1		Andrew, David P. et al.							
14	424/143.1; 424/144.1; 435/7.92		Qin, Shixin et al.	⊠						

		mage Doc. Displayed	PT
10	US	6140064	
11	US	6165476	
12	US	6184358	
13	US	6329159	·
14	US	6329510	

East: recombinant adjatenterferon and polyviny/ prro lone

,	ט	1	Dө	cument ID	Issue Date	Pages	Title	Current OR
1	×		US A	4636383	19870113	6	Interferon-cyclaradine combination	424/85.7
2	⊠		US A	5086044	19920204	6	Treatment of human viral infections	514/51
3			US A	5093114	19920303	6	Treatment of human viral infections	424/85.4
4			US A	5093116	19920303	10	Method of treating viral infection utilizing inteferon alpha. and pipyridamole	424/85.7
5			US A	5198350	19930330	19	Interferon-induced human protein in pure form, monoclonal antibodies thereto and test kits containing these antibodies	435/91.41
6	⊠		US A	5466585	19951114	22	Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies	435/69.1
7			US A	5496266	19960305	14	Device and method of iontophoretic drug delivery	604/20
8	×		US A	5647844	19970715	13	Device and method of iontophoretic drug delivery	604/20
9	⊠		US A	5739290	19980414	20	Monoclonal antibody against an interferon-induced human protein in pure form	530/388.2
10	⊠	1 1 :	US A	5780597	19980714	71	Monoclonal antibodies to cytotoxic lymphocyte maturation factor	530/388.23
11	⊠		US A	5849800	19981215	9	Use of amantadine for treatment of Hepatitis C	514/647
12	⊠		US A	5857992	19990112	13	Device and method of iontophoretic drug delivery	604/20
13	⊠		US A	5869264	19990209	21	Immunoassays for and immunopurification of interferon-induced human protein	435/7.1

	Current	Retrieval				I _	Ι_		Γ.	
	XRef	Classif	Inventor	ធ	С	P	2	3	4	5
1	424/85.4; 435/71.1		Nagabhushan, Tattanahali L. et al.							
2	514/934		Rideout, Janet L. et al.							
3	424/85.5; 424/85.7; 514/5		Rideout, Janet L. et al.							
4	514/262.1; 514/889		Suzuki, Nobuo							
5	435/488; 435/91.51; 435/91.53; 530/350; 530/387.9; 530/388.2; 536/23.5		Horisberger, Michel A. et al.							
6	435/252.3; 435/252.33 ; 435/320.1; 536/23.1; 536/23.5		Horisberger, Michel A. et al.							
7	604/19		Haak, Ronald P. et al.							
8	424/449		Haak, Ronald P. et al.							
9	435/331; 435/69.1; 530/388.1; 530/391.1		Horisberger, Michel Andre et al.							
10	530/351; 530/387.1; 530/389.2; 530/806		Gately, Maurice Kent et al.							
11			Smith, Jill P.							
12	607/115		Haak, Ronald P. et al.							
13	530/388.1		Horisberger, Michel Andre et al.							

	I	mage Doc. Displayed	PT
1	US	4636383	
2	us	5086044	
3	US	5093114	
4	US	5093116	
5	US	5198350	
6	US	5466585	
7	US	5496266	
8	US	5647844	
9	US	5739290	
10	US	5780597	
11	US	5849800	
12	US	5857992	
13	US	5869264	

	ט	1	Document	: ID	Issue Date	Pages	Title	Current OF
14	×		US 59812 A	77 1	19991109	76	Polypeptides and peptides, nucleic acids coding for them, and their use in the field of tumor therapy, inflammation or immunology	435/325
15	⊠		US 59934 A	35 1	19991130	13	Device and method of iontophoretic drug delivery	604/501
16	×		US 61333 A	09 2	20001017	11	Treatment of T-helper cell type 2-mediated immune disease by retinoid antagonists	514/432
17	×		US 61532 A	12 2	20001128	19	Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same	424/426
18	⊠		US 62007 B1	80 2	20010313	52	Human interferonepsilon.(IF Nepsilon.), a type I interferon	435/69.51
19	⊠		US 62998 B1	60	20011009		Human interferon-epsilon: a type I interferon	424/85.4

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
14	435/252.3; 435/252.33; 435/254.11; 435/320.1; 435/364; 435/367; 435/455; 536/23.1; 536/23.5; 536/24.1; 536/24.33		Fransen, Lucia et al.							
15	604/20		Haak, Ronald P. et al.							
16			Bollag, Werner et al.							
17	514/772.3		Mao, Hai-quan et al.							
18	424/85.4; 435/252.3; 435/252.33; ; 435/254.2; 435/320.1; 435/325; 435/325; 435/358; 530/351; 536/23.52		Chen, Jian et al.							
19	435/252.33; 435/320.1; 435/325; 435/358; 435/69.1; 435/69.2; 435/69.51; 514/12; 514/2; 530/350; 530/351; 536/23.1; 536/23.52		Chen, Jian et al.							

	I	mage Doc. Displayed	PT
14	US		
15	US	5993435	
16	US	6133309	
17	US	6153212	Ö
18	US	6200780	
19	US	6299869	

	U	1	Do	cument ID	Issue Date	Pages	Title	Current OR
20	×		US B1	6312924	20011106	44	Murine interferonalpha.	435/69.51
21			US B1	6322797	20011127	40	Biodegradable terephthalate polyester-poly (phosphate) polymers, compositions, articles, and methods for making and using the same	424/78.37
22			US B1	6326388	20011204	14	Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level	514/364
23	⊠		US B1	6326397	20011204	24	Retinoid antagonists and use thereof	514/531
24	⊠		US B1	6329175	20011211	59	Interferonepsilon.	435/69.51
25			US B1	6329381	20011211	66	Heterocyclic compounds	514/263.23
26			US B1	6344464	20020205	14	Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination	514/315

ſ		
`	- 3	

	Current XRef	Retrieval Classif	Inventor	s	С	P	2	3	4	5
20	435/252.8; 435/254.11; 435/320.1; 435/325; 435/348; 435/349; 435/419; 435/70.5; 514/2; 530/351; 536/23.1; 536/23.52		Presnell, Scott R. et al.							
21	428/378; 442/248; 523/115; 528/398		Mao, Hai-Quan et al.							
22	546/134; 548/131		Man, Hon-Wah et al.							
23	514/502; 514/570; 554/218; 560/55; 560/59; 562/465; 562/469; 568/442		Bollag, Werner et al.							
24	435/252.3; 435/254.1; 435/255.1; 435/320.1; 435/325; 435/348; 435/349; 435/410; 530/351; 536/23.52		Conklin, Darrell C. et al.							
25	514/263.36 ; 514/263.4		Kurimoto, Ayumu et al.							
26	514/318		Bourrie, Bernard et al.	⊠						

	•	mage Doc. Displayed	PT
20	US	6312924	
21	US	6322797	
22	US	6326388	
23	US	6326397	
24	US	6329175	
25	US	6329381	
26	US	6344464	

East: Inventors'name securch

(Petr near Gaponjuk )01

. nor (5	lena	near harko	
		———  ~·  )	

	υ	1	Document ID	Issue Date	Pages	Title	Current OR
1			EP 437636 A1	19910724	10	DEVICE FOR LOCATING AND INFLUENCING ACUPUNCTURE POINTS.	1

	Current XRef	Retrieval Classif	Inventor	s	C	P	2	3	4	5
1			ZHUKOV, DMITRY SERGEEVICH et al.	×						

•		ı	mage Do Display		PT
	1	ΕP	437636	A1	